Breast cancer and timing of surgery during menstrual cycle: a 5‐year analysis of 248 premenopausal women
Michele Stanislaw Milella(University of Verona), Paola Papaldo(Cancer Institute (WIA)), Virginia Ferraresi(Cancer Institute (WIA)), Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Alessandra Fabi(Agostino Gemelli University Polyclinic), Francesco Cognetti(Apple (Israel)), Angela Vaccaro(Accademia di Belle Arti di Frosinone), Mauro Antimi(Catholic University of America), Carlo Maria Foggi, Diana Giannarelli(Agostino Gemelli University Polyclinic), Enrico Cortesi(Sapienza University of Rome), A.M. D'Ottavio(Cancer Institute (WIA)), Claudio Botti(Catholic University of America), Massimo Lopez(Catholic University of America), E. Terzoli(Catholic University of America)
Cited by 17
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k